Coverage of Accessory Renal Arteries During Endovascular Aortic Aneurysm Repair: What Are the Consequences and the Implications for Clinical Practice?


Journal

Angiology
ISSN: 1940-1574
Titre abrégé: Angiology
Pays: United States
ID NLM: 0203706

Informations de publication

Date de publication:
Jan 2019
Historique:
pubmed: 24 4 2018
medline: 7 3 2019
entrez: 24 4 2018
Statut: ppublish

Résumé

An accessory renal artery (ARA) represents an anatomic variation which can challenge endovascular aortic aneurysm repair (EVAR). The aim of this review was to summarize the current knowledge on postoperative outcomes following ARA coverage during EVAR. We performed a systematic literature review. The MEDLINE database was searched on September 2017, and 8 relevant studies were included. The frequency of ARA in patients undergoing EVAR varied between 9.5% and 16.2%, and the frequency of ARA coverage varied between 5.2% and 9.4%. Four reports did not observe any significant changes on postoperative renal function, whereas 1 study reported an early transient increase in creatinine after ARA coverage. The occurrence of renal infarct varied from 20% to 84%. Five studies did not observe endoleaks related to ARA coverage, whereas one reported the occurrence of type II endoleaks in 3 of 18 patients who had ARA coverage. No significant change in blood pressure, mortality, and mean length of hospital stay was observed. The ARA coverage can potentially have renal and vascular consequences, but none of them were critical. Further studies may be useful to identify preoperative criteria that may help to choose the most appropriate surgical approach before ARA coverage.

Identifiants

pubmed: 29682989
doi: 10.1177/0003319718771249
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

12-19

Auteurs

Fabien Lareyre (F)

1 Department of Vascular Surgery, University Hospital of Nice, Nice, France.
2 Department of Clinical Biochemistry, University of Côte d'Azur, Inserm, C3M, France.

Frédéric Panthier (F)

3 Department of Urology, Tenon University Hospital, University of Pierre et Marie Curie, Paris, France.

Elixène Jean-Baptiste (E)

1 Department of Vascular Surgery, University Hospital of Nice, Nice, France.
2 Department of Clinical Biochemistry, University of Côte d'Azur, Inserm, C3M, France.

Réda Hassen-Khodja (R)

1 Department of Vascular Surgery, University Hospital of Nice, Nice, France.
2 Department of Clinical Biochemistry, University of Côte d'Azur, Inserm, C3M, France.

Juliette Raffort (J)

2 Department of Clinical Biochemistry, University of Côte d'Azur, Inserm, C3M, France.
4 Department of Clinical Biochemistry, University Hospital of Nice, Nice, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH